Chronic liver diseases of differing etiologies are among the leading causes of mortality and morbidity worldwide. Establishing accurate staging of liver disease is very important for enabling both therapeutic decisions and prognostic evaluations. A liver biopsy is considered the gold standard for assessing the stage of hepatic fibrosis, but it has many limitations. During the last decade, several noninvasive markers for assessing the stage of hepatic fibrosis have been developed. Some have been well validated and are comparable to liver biopsy. This chapter will focus on the various noninvasive biochemical markers used to stage liver fibrosis.
Keywords: AAR, APRI, Biomarkers, Collagen, Cirrhosis, Chronic liver diseases, ELF, FIB-4, Fibrosis, FibroIndex, FibroMeter, FibroQ, FibroTest, Fibrospect, Forns, HepaScore, PGA, SHASTA, YKL-40, Hyaluronic acid, Laminin, Liver biopsy, Metalloproteinases, Procollagen, Transforming growth factor.